Accessibility Menu
Absci logo

Absci(NASDAQ) ABSI

Market Cap$1.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-56%
5 Year-58%
1 Year+273%
1 Month+16%
Premium Feature
Moneyball Superscore
52/100
$8.81
-7.75%
-0.74Today
After hours$8.85+$0.04 (+0.45%)
Absci last closing stock price
MetricPriceDate
Last closeUSD 9.552026-08-21
Absci stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.03%USD 9.182026-08-14
1 month+15.9%USD 8.242026-07-22
3 month+87.25%USD 5.102026-05-22
Year to date+173.64%USD 3.492025-12-31
1 year+273.05%USD 2.562025-08-21
3 year+528.29%USD 1.522023-08-22
5 year-57.59%USD 22.522021-08-20
Since inception-55.77%USD 21.592021-07-22

Absci Financials at a Glance

Market Cap

$1.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.56M

Net Income (TTM)

-$121.08M

EPS (TTM)

-$0.80

P/E Ratio

-11.04

Dividend

$0.00

Beta (Volatility)

2.25 (High)

Price

$8.81

Volume

2,203,547.718

Open

$9.33

Previous Close

$8.84

Daily Range

$8.75 - $9.36

52-Week Range

$2.24 - $12.06

Estimated Earnings Date

Nov 16, 2026

ABSI News

A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsJul 10, 2026
GettyImages-1411285056

The 1 AI Stock I'd Put in a Time Capsule and Open in 2036

Micah ZimmermanMay 25, 2026
Foolcom-Featured.png

Absci Sales Fall 54 Percent

Motley Fool Markets TeamAug 12, 2025

ABSI: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Absci

Absci Corporation uses artificial intelligence to create new medicines. The company designs specialized proteins that help fight human diseases. This technology makes discovering new drugs faster and more efficient.

Designing Better Antibodies

  • ABS-201: Antibody treatment for hair loss and endometriosis currently in clinical trials.
  • ABS-202: Preclinical drug candidate designed to treat inflammation and immune-related diseases.
  • Origin-1: Generative artificial intelligence model used to design new drug candidates from scratch.
  • Drug Creation Platform: Integrated system that combines computer design with rapid laboratory testing.

Partnerships and Clinical Progress

  • Entered a strategic collaboration with Advanced Micro Devices, Inc. in Jan. 2025 to optimize software for drug design.
  • Raised $20.0 million from a private stock sale to Advanced Micro Devices, Inc. in Jan. 2025.
  • Completed a public stock offering in June 2026 that generated $93.6 million in net proceeds.
  • Started a clinical trial in Australia to test ABS-201 as a potential treatment for pattern hair loss.

Why the Technology Matters

Absci operates research facilities in Washington, New York, Switzerland, and Serbia to support its global development efforts. The company reports it can advance drug programs from design to testing in two years, compared to the industry average of four to six years.

Recent Financial Performance

  • Partner program revenue was $318,000 for the three months ended June 30, 2026, down 46% year over year.
  • Net loss reached $62.8 million for the six months ended June 30, 2026.
  • Research and development expenses increased 14% to $41.9 million for the six months ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities totaled $201.1 million as of June 30, 2026.
  • The company reported an accumulated deficit of $687.6 million as of June 30, 2026.

Bottom Line

Absci has evolved from a technology provider into a clinical-stage biotechnology firm with its own drug pipeline. Its growth depends on using artificial intelligence to reduce the time and cost of creating new biologic therapies.

AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

140

CEO

Sean McClain

Website

www.absci.com

Headquarters

Vancouver, WA 98683, US

ABSI Financials

Key Financial Metrics (TTM)

Gross Margin

-255.93%

Operating Margin

-8411.27%

Net Income Margin

-7756.37%

Return on Equity

-59.21%

Return on Capital

-64.04%

Return on Assets

-45.02%

Earnings Yield

-9.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

171.61M

Volume

2.20M

Avg. Volume

5.03M

Financials (TTM)

Gross Profit

-$4.00M

Operating Income

-$131.30M

EBITDA

-$109.93M

Operating Cash Flow

-$108.08M

Capital Expenditure

-$890.00K

Free Cash Flow

-$108.97M

Cash & ST Invst.

$201.14M

Total Debt

$3.68M

Absci Performance Analysis

Absci annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,747,00020.2%
20232023-12-31USD 5,718,000-0.5%
20242024-12-31USD 4,534,000-20.7%
20252025-12-31USD 2,800,000-38.2%
Absci sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-36.3%
Q42025-12-3172.0%
Q12026-03-31-66.9%
Q22026-06-3047.9%
Absci annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.153.6%
20232023-12-31USD -1.204.0%
20242024-12-31USD -0.94-22.1%
20252025-12-31USD -0.84-10.0%
Absci sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.7%
Q42025-12-31N/A
Q12026-03-315.0%
Q22026-06-30-10.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$318.00K

-46.4%

Gross Profit

$318.00K

+101.6%

Gross Margin

100.00%

N/A

Market Cap

$1.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.84M

N/A

Employees

140

N/A

Net Income

-$33.21M

-8.6%

EBITDA

-$30.47M

-11.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$201.14M

+71.2%

Total Debt

$3.68M

-50.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$1.64M

-55.8%

Short Term Debt

$2.04M

-44.9%

Return on Assets

-45.02%

N/A

Return on Invested Capital

-52.66%

N/A

Free Cash Flow

-$27.57M

-61.2%

Operating Cash Flow

-$27.56M

-63.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MGTXMeiraGTx Holdings plc
$14.83+3.42%
MLTXMoonLake Immunotherapeutics
$15.37-2.47%
CRVSCorvus Pharmaceuticals, Inc.
$14.09-2.56%
VTYXVentyx Biosciences, Inc.
$14.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$208.48-0.03%
BITOProShares Trust - ProShares Bitcoin ETF
$10.63+0.02%
INTCIntel
$87.26-0.03%
IBITiShares Bitcoin Trust
$44.64+0.02%

Questions About ABSI

What is the current price of Absci?

Absci is trading at $8.84 per share.

What is the 52-week range for Absci?

Over the past 52 weeks, Absci has traded between $2.24 and $12.06.

How much debt does Absci have?

As of the most recent reporting period, Absci reported total debt of $3.83M.

How much cash does Absci have on hand?

Absci reported $107.87M in cash and cash equivalents in its most recent financial results.

What is Absci’s dividend yield?

Absci does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services